PMID- 35667836
OWN - NLM
STAT- MEDLINE
DCOM- 20220914
LR  - 20220914
IS  - 1423-0410 (Electronic)
IS  - 0042-9007 (Linking)
VI  - 117
IP  - 9
DP  - 2022 Sep
TI  - The spectrum of ABO haemolytic disease of the fetus and newborn in neonates born 
      to group O mothers.
PG  - 1112-1120
LID - 10.1111/vox.13327 [doi]
AB  - BACKGROUND AND OBJECTIVES: ABO haemolytic disease of the fetus and newborn (HDFN) 
      is a lesser recognized entity; however, the severity may vary in neonates. This 
      prospective observational study was performed to determine the severity and risk 
      of ABO-HDFN in neonates born to O group mothers. MATERIALS AND METHODS: A total 
      of 260 neonates born to non-alloimmunized blood group O mothers were recruited. 
      Blood group O neonates were excluded from the study. Neonatal direct antiglobulin 
      test (DAT) was performed using the column agglutination technique. They were 
      monitored for clinical and laboratory parameters and followed up at 6-8 weeks. 
      The maternal anti-A and anti-B titres (IgM and IgG) were also done. RESULTS: A 
      total of 176 neonates with blood group A (77/260; 29.6%) and B (99/260; 38.1%) 
      were finally included in the study, and 15 (8.5%) of them were DAT positive. 
      Overall, 26.7% (47/176) neonates received phototherapy, 172 (97.7%) survived and 
      none required readmission. The median (inter-quartile range [IQR]) maternal IgG 
      anti-B titre (32 [32-64]) was significantly higher (p < 0.001) than the IgG 
      anti-A titre (16 [8-64]). The maximum total serum bilirubin in neonates had a 
      significant positive association with neonatal birth weight (p = 0.045), positive 
      DAT (p = 0.006) and requirement of phototherapy (p < 0.001). The relative risk 
      (95% CI) of a DAT-positive neonate requiring phototherapy was 4.55 (3.12-6.33). 
      CONCLUSION: The frequency of ABO incompatibility in neonates born to group O 
      mothers was 67.69% (176/260). The maternal IgG titre of >/=64 could be a good 
      predictor for identifying the neonates at risk of developing hyperbilirubinaemia 
      requiring phototherapy.
CI  - (c) 2022 International Society of Blood Transfusion.
FAU - Talwar, Manvi
AU  - Talwar M
AD  - Department of Transfusion Medicine, Postgraduate Institute of Medical Education 
      and Research (PGIMER), Chandigarh, India.
FAU - Jain, Ashish
AU  - Jain A
AUID- ORCID: 0000-0001-7799-7484
AD  - Department of Transfusion Medicine, Postgraduate Institute of Medical Education 
      and Research (PGIMER), Chandigarh, India.
FAU - Sharma, Ratti Ram
AU  - Sharma RR
AUID- ORCID: 0000-0002-7415-4665
AD  - Department of Transfusion Medicine, Postgraduate Institute of Medical Education 
      and Research (PGIMER), Chandigarh, India.
FAU - Kumar, Praveen
AU  - Kumar P
AD  - Department of Pediatric Medicine, Postgraduate Institute of Medical Education and 
      Research (PGIMER), Chandigarh, India.
FAU - Saha, Subhas Chandra
AU  - Saha SC
AD  - Department of Obstetrics and Gynecology, Postgraduate Institute of Medical 
      Education and Research (PGIMER), Chandigarh, India.
FAU - Singh, Lakhvinder
AU  - Singh L
AUID- ORCID: 0000-0002-7658-5389
AD  - Department of Transfusion Medicine, Postgraduate Institute of Medical Education 
      and Research (PGIMER), Chandigarh, India.
LA  - eng
GR  - None declared./
PT  - Journal Article
PT  - Observational Study
DEP - 20220606
PL  - England
TA  - Vox Sang
JT  - Vox sanguinis
JID - 0413606
RN  - 0 (ABO Blood-Group System)
RN  - 0 (Immunoglobulin G)
SB  - IM
MH  - ABO Blood-Group System
MH  - *Blood Group Incompatibility
MH  - *Erythroblastosis, Fetal
MH  - Female
MH  - Fetus
MH  - Humans
MH  - Immunoglobulin G
MH  - Infant, Newborn
OTO - NOTNLM
OT  - ABO-HDFN
OT  - IgG antibody
OT  - antibody titre
OT  - direct antiglobulin test
OT  - haemolytic disease of the fetus and newborn
EDAT- 2022/06/07 06:00
MHDA- 2022/09/15 06:00
CRDT- 2022/06/06 21:12
PHST- 2022/04/23 00:00 [revised]
PHST- 2022/02/22 00:00 [received]
PHST- 2022/05/15 00:00 [accepted]
PHST- 2022/06/07 06:00 [pubmed]
PHST- 2022/09/15 06:00 [medline]
PHST- 2022/06/06 21:12 [entrez]
AID - 10.1111/vox.13327 [doi]
PST - ppublish
SO  - Vox Sang. 2022 Sep;117(9):1112-1120. doi: 10.1111/vox.13327. Epub 2022 Jun 6.